Listing 14.03 Systemic Vasculitis in 2026: The Two Paths to Approval, ANCA-Associated Disease Documentation, and How Giant Cell Arteritis, GPA, EGPA, and Polyarteritis Nodosa Fit the SSA Framework

By Anthony Albert, Benefits Research Director, Disability Exchange · Published July 14, 2026

Vasculitis is a family of diseases where the immune system attacks blood vessels. Depending on which vessels get hit and where, the presentation can look like almost anything. Kidney failure. Lung hemorrhage. Blindness. Stroke. Bowel infarction. Digital gangrene. Chronic sinus disease with saddle nose deformity. The clinical face of vasculitis is so variable that most primary care doctors have never seen a case in person, and diagnosis often comes late.

Listing 14.03 gives SSA a workable framework to evaluate this messy disease category. Two paths. Path A covers multi-organ involvement with constitutional symptoms. Path B covers the more chronic, relapsing course with marked functional impairment. Both work. Neither requires you to fit into a specific vasculitis subtype. GPA, MPA, EGPA, PAN, Takayasu, giant cell arteritis, Henoch-Schonlein purpura, cryoglobulinemic vasculitis, IgG4-related disease with vasculitic features, and Behcet's all get evaluated under 14.03 (though HSP and Behcet's have their own quirks).

This article walks through both paths, what "moderate severity" means for each subtype, how ANCA testing and biopsy findings support the case, and two 2026 worked approvals.

What SSA means by systemic vasculitis

Section 14.00D2 defines systemic vasculitis as inflammation of blood vessels, which can be small, medium, or large caliber. The inflammation compromises blood flow, damages the vessel wall, and causes downstream tissue injury. The main subtypes SSA recognizes:

• Polyarteritis nodosa (PAN): medium-vessel vasculitis, often associated with hepatitis B. Can affect kidneys, GI tract, peripheral nerves, skin.
• Takayasu arteritis: large-vessel vasculitis affecting the aorta and its major branches. Diagnosed by imaging (angiography, MRA, PET). Causes limb claudication, pulseless arms, hypertension, and stroke risk.
• Giant cell arteritis (GCA, temporal arteritis): large-vessel vasculitis affecting the aorta and cranial arteries, typically in patients over 50. Classic presentation includes headaches, jaw claudication, visual disturbance, and polymyalgia rheumatica overlap. Untreated GCA can cause permanent blindness.
• Granulomatosis with polyangiitis (GPA, formerly Wegener's): ANCA-associated vasculitis affecting upper airway (sinuses, nasal cartilage), lower airway (lungs), and kidneys. c-ANCA/PR3 positive.
• Microscopic polyangiitis (MPA): ANCA-associated small-vessel vasculitis affecting lungs and kidneys. p-ANCA/MPO positive.
• Eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss): ANCA-associated vasculitis with asthma, peripheral eosinophilia, and multi-organ involvement.
• Henoch-Schonlein purpura (HSP, IgA vasculitis): palpable purpura, joint pain, abdominal pain, and IgA nephropathy.

Beyond these SSA-named subtypes, cryoglobulinemic vasculitis (often hepatitis C associated), Behcet's disease, IgG4-related disease with vasculitic features, and drug-induced vasculitides all get evaluated under 14.03 with the same A/B path structure.

Path A: Two or more organs with constitutional symptoms

Path A requires:

• Involvement of two or more organs or body systems, with at least one at moderate severity, AND
• At least two of the constitutional symptoms or signs: severe fatigue, fever, malaise, or involuntary weight loss.

Organs and body systems that count for vasculitis:

• Kidney: glomerulonephritis, proteinuria, hematuria, elevated creatinine, or full renal failure. Moderate severity typically means CKD stage 3+ (eGFR under 60) or significant proteinuria (over 1 g/24 hr).
• Lung: alveolar hemorrhage, interstitial lung disease from GPA or MPA, cavitary nodules, or asthma component in EGPA. Moderate severity typically means FVC 60-75% predicted or documented alveolar hemorrhage.
• Peripheral nerve: mononeuritis multiplex causing motor weakness or sensory loss. EMG/NCS documentation supports this.
• Skin: palpable purpura, digital ischemia, ulcerations, gangrene. Moderate severity means significant skin involvement with functional impact.
• GI tract: mesenteric ischemia, bowel infarction, GI bleeding.
• Central nervous system: stroke, encephalopathy, cranial neuropathy.
• Upper airway (GPA-specific): chronic sinusitis, nasal cartilage destruction, saddle nose deformity, subglottic stenosis.
• Cardiac: myocarditis, pericarditis, coronary vasculitis.
• Eye: scleritis, uveitis, ischemic optic neuropathy (especially in GCA).

Two of these organs with one at moderate severity, plus two constitutional symptoms documented in provider notes, meets Path A.

Path B: Repeated manifestations with marked functional limitation

Path B requires:

• Repeated manifestations of systemic vasculitis, AND
• At least two constitutional symptoms or signs, AND
• One of the following at a MARKED level:
  1. Limitation of activities of daily living
  2. Limitation in maintaining social functioning
  3. Limitation in completing tasks in a timely manner due to deficiencies in concentration, persistence, or pace

Path B fits patients whose disease has a relapsing-remitting pattern with multiple flares over time and significant functional impact even between flares. The chronic fatigue, steroid side effects, immunosuppression risk, and cumulative organ damage often add up to marked functional limitation even when any single organ isn't at the moderate-severity threshold on Path A.

"Marked" is a specific term in SSA disability law. It's less than "extreme" but more than "moderate." It's a limitation that seriously interferes with your ability to function independently, appropriately, effectively, and on a sustained basis.

ANCA testing and biopsy findings

Diagnosis of ANCA-associated vasculitis (GPA, MPA, EGPA) relies on:

• Serologic testing: anti-neutrophil cytoplasmic antibody (ANCA) with c-ANCA/PR3 pattern typical of GPA, p-ANCA/MPO pattern typical of MPA and some EGPA. Positive ANCA supports the diagnosis but isn't required if biopsy is diagnostic.
• Biopsy: tissue diagnosis is the gold standard. Kidney biopsy showing pauci-immune necrotizing glomerulonephritis, lung biopsy showing granulomatous vasculitis, nasal or sinus biopsy showing granulomatous inflammation, skin biopsy showing leukocytoclastic vasculitis, or nerve biopsy showing vasculitic neuropathy.
• ACR/EULAR 2022 classification criteria: current diagnostic framework, with weighted scoring for each subtype.

DDS doesn't require any particular test result. What matters is that the diagnosis is documented and the organ involvement is measurable. But strong serology (high ANCA titer) plus biopsy confirmation supports the case, especially when DDS medical consultants review.

For large-vessel vasculitis (Takayasu, GCA), diagnosis often relies on imaging:

• Temporal artery biopsy: for GCA, showing giant cells and disrupted internal elastic lamina.
• MR angiography or CT angiography: for Takayasu, showing large-vessel wall thickening or stenosis.
• Vascular ultrasound: for temporal arteries in GCA, showing the halo sign.
• PET-CT: for large-vessel vasculitis, showing FDG uptake in inflamed vessel walls.

Constitutional symptoms in vasculitis

Constitutional symptoms are heavily represented in active vasculitis:

• Severe fatigue: nearly universal in active disease. Providers should document that fatigue interferes with daily activities and work.
• Fever: low-grade fevers (99-101 F) are common; higher fevers occur with active flares or with concurrent infections related to immunosuppression.
• Malaise: feeling generally unwell, often described alongside fatigue.
• Involuntary weight loss: common with active disease, especially GPA and PAN. 10+ pounds over 6-12 months supports the criterion.

Ask your rheumatologist to chart these symptoms with specific descriptors on every visit. "Patient reports severe fatigue requiring 2-3 hour daily rest" is stronger than "fatigue noted." Weight should be tracked visit-to-visit so involuntary loss is documented with numbers.

Worked case A: Renee, 55, Boston MA, granulomatosis with polyangiitis

Worked case B: David, 67, Phoenix AZ, giant cell arteritis with visual loss

Common denial reasons and how to counter them

1. DDS says only one organ is involved. Counter by broadening the review to include every affected system. Kidney AND skin AND nerves AND constitutional symptoms often add up to multi-system disease even when the "main" issue is one organ.
2. DDS says the organ involvement isn't at moderate severity. Counter by citing specific measurable thresholds: eGFR, FVC, alveolar hemorrhage documentation, EMG evidence of mononeuritis multiplex, imaging showing vascular involvement.
3. DDS doesn't find constitutional symptoms in the chart. Counter by having your rheumatologist write an addendum specifying severe fatigue with functional impact, involuntary weight loss with specific numbers, malaise, or documented fevers.
4. DDS treats vasculitis as "in remission" and denies. Counter by documenting the frequency of flares, need for chronic immunosuppression, cumulative organ damage, and the functional impact between flares. Path B is designed for exactly this pattern.
5. DDS says the diagnosis isn't definitive. Counter by producing the biopsy report (kidney, lung, nasal, skin, nerve, temporal artery) and ANCA serology. If diagnosis is clinical (imaging-based large-vessel vasculitis without biopsy), get a rheumatology attestation citing the ACR/EULAR criteria met.

2026 treatment context

Vasculitis treatment has changed dramatically in the past decade:

• Rituximab is now first-line for many ANCA-associated vasculitides (GPA, MPA) and increasingly used in EGPA. Maintenance every 4-6 months.
• Avacopan is a complement C5a receptor inhibitor approved for GPA and MPA, allowing lower prednisone doses.
• Mepolizumab (anti-IL-5) is used for EGPA with eosinophilic features.
• Tocilizumab (anti-IL-6) is approved for giant cell arteritis as a steroid-sparing agent.
• Cyclophosphamide is still used for severe organ-threatening disease.
• Prednisone remains the fastest-acting agent for acute flares.

Aggressive treatment can put many patients into deep remission. That doesn't automatically end SSDI eligibility. Cumulative organ damage from prior disease activity persists. Chronic immunosuppression carries infection risk and functional cost. And relapses are frequent enough that "remission" isn't the same as "cured."

Continuing disability review considerations

Vasculitis approvals often get medium-frequency CDRs (every 3-5 years). If your disease has stabilized on maintenance therapy and the previously moderate-severity organ involvement has improved (renal function recovered, lung disease stable), CDR may look at whether you still meet 14.03. Damage from prior flares typically persists (CKD from prior glomerulonephritis doesn't reverse), which supports ongoing eligibility.

For Path B cases based on repeated manifestations and marked functional limitation, the ongoing pattern of flares and functional impairment continues to support the listing as long as it continues.

State pages and related listings

• Massachusetts SSDI resources
• Arizona SSDI resources
• New York SSDI resources

• Listing 14.04 Systemic Sclerosis / Scleroderma SSDI 2026
• Listing 14.02 Systemic Lupus Erythematosus SSDI 2026
• Listing 3.07 Bronchiectasis SSDI 2026

Frequently asked questions